Loading...
Market
Will seladelpar achieve over 50% market share in the EU PBC treatment market by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports or industry analysis publications
Story
Gilead's Seladelpar Gets Positive CHMP Opinion for PBC, Shows 62% Response Rate
Dec 13, 2024, 11:39 AM
Gilead Sciences, Inc. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug seladelpar, intended for the treatment of primary biliary cholangitis (PBC) in adults. The recommendation is based on the results from the pivotal placebo-controlled Phase 3 RESPONSE study, which demonstrated that seladelpar achieved a composite biochemical response in 62% of participants at month 12, compared to 20% with placebo. Additionally, 25% of participants on seladelpar normalized their alkaline phosphatase (ALP) levels, a key marker of disease progression in PBC. The drug also significantly reduced pruritus, a common and debilitating symptom of PBC. If approved by the European Commission, seladelpar would provide an important new treatment option for PBC patients in the EU, where the disease affects approximately 15 per 100,000 people, primarily women.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%
